Synthetic GHRH(1-29)-NH₂ / growth hormone-releasing hormone receptor agonist

Sermorelin

INN: sermorelin CAS: 86168-78-7 MW: 3357.93 g/mol Formula: C₁₄₉H₂₄₆N₄₄O₄₂S

Key Takeaways

  • Adult longevity / “anti-aging” evidence reduces to a small 1990s trial cluster (Corpas 1992 n=10/9; Vittone 1997 n=11; Khorram 1997 n=19) and has not been refreshed by an adequately powered RCT in nearly three decades; the class-level Liu 2007 Annals of Internal Medicine systematic review concluded GH cannot be recommended as anti-aging therapy in healthy elderly adults.
  • FDA approval (Geref NDA 020443) was withdrawn 2009-06-18 for commercial — not safety or efficacy — reasons; sermorelin remains compoundable under §503A as a component of a previously FDA-approved drug, distinguishing it operationally from CJC-1295, ipamorelin, BPC-157 and other peptides that lost compounding access in 2024. WADA 2026 Prohibited List Section S2.2.4 names sermorelin explicitly.
  • Community Score 85 (A). Near-monolithic “200–300 mcg subcutaneous before bed, 5 nights/week” clinic protocol reproduced across Defy, Eden, HydraMed, Olympia, Sermorelin.com, Strive, Atlas, and BodyLogicMD-style chains; ~20 years of optimization-audience circulation; positioning consolidated post-2024 as the sole legally compoundable GHRH-axis peptide in the US.
  • The clinic-standard 200–300 mcg dose is 3–4× lower than the 10 µg/kg dose (~800 mcg for an 80 kg adult) used in Khorram 1997; community forums (MESO-Rx, r/Peptides-adjacent) consistently flag the disconnect, and IGF-1 movement on clinic-prescribed doses is inconsistently reported.
  • Body-composition and immune findings concentrate in a single research group 🔴 (Khorram / Yen, UCSD, 1997) and have not been replicated since.

1. Identity

FieldValueSource
INNsermorelin[Academic secondary source — WHO INN list; DrugBank DB00010]
Other namesGHRH(1-29)-NH₂; GRF(1-29); somatorelin[Academic secondary source — DrugBank DB00010; PubChem CID 16132413]
CAS (free base)86168-78-7[Academic secondary source — PubChem CID 16132413]
CAS (acetate salt)114466-38-5[Academic secondary source — PubChem CID 16132412]
Molecular formula (free base)C₁₄₉H₂₄₆N₄₄O₄₂S[Academic secondary source — PubChem CID 16132413]
Molecular weight (free base)3357.93 g/mol[Academic secondary source — PubChem CID 16132413]
SequenceTyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂ (29 aa, C-terminal amide)[Academic secondary source — DrugBank DB00010; Peer-reviewed secondary — Prakash & Goa 1999]
ClassSynthetic peptide; growth hormone-releasing hormone (GHRH) receptor agonist[Academic secondary source — IUPHAR/BPS GtoPdb GHRH receptor entry]
Brand names (historical)Geref® (0.5 mg, 1.0 mg s.c.); Geref Diagnostic® (0.05 mg i.v.)[Regulatory document — FDA NDA 020443; NDA 019863]
FDA NDA numbers020443 (therapeutic, 1997); 019863 (diagnostic, 1990) — both withdrawn 2009-06-18[Regulatory document — FDA Federal Register 74 FR 23407; 78 FR 13900]
Marketing authorization holder (historical)Serono Laboratories / EMD Serono[Regulatory document — FDA 78 FR 13900]
ATC codeH01AC04 (somatotropin agonists — GHRH analogues)[Academic secondary source — WHO ATC index]
Plasma half-life~11–12 minutes[Peer-reviewed human study — Thorner 1986; Prakash & Goa 1999]

2. History and Development

Sermorelin traces to the 1982 isolation of human pancreatic GHRH from two ectopic GHRH-secreting tumors by Guillemin and colleagues at the Salk Institute, and parallel sequencing work by Schally’s group at Tulane [Peer-reviewed — Guillemin 1982 Science 218:585; Rivier 1982 Nature 300:276]. The 44-amino-acid full-length GHRH was rapidly truncated to define a minimum bioactive fragment; GHRH(1-29)-NH₂ was identified as the shortest C-terminally amidated sequence retaining full somatotroph-stimulating potency [Peer-reviewed preclinical — Ling 1984; Thorner 1986 JCEM 63:638].

Serono Laboratories developed the synthetic peptide as Geref. FDA approval history:

  • NDA 019863 (Geref Diagnostic, 0.05 mg/amp, i.v. bolus): approved 1990-12-28 for evaluating somatotroph capacity to secrete GH [Regulatory document — FDA NDA 019863].
  • NDA 020443 (Geref, 0.5 mg and 1.0 mg/vial, s.c.): approved 1997-09-26 for treatment of idiopathic growth hormone deficiency (GHD) in children with growth failure [Regulatory document — FDA NDA 020443; Federal Register 78 FR 13900].

EMD Serono notified FDA by letters dated 2008-07-11 and 2008-12-02 that both products were being discontinued and requested withdrawal of NDA 019863 and NDA 020443. FDA published withdrawal of approval in the Federal Register on 2009-05-19 (74 FR 23407), effective 2009-06-18 [Regulatory document — FDA 74 FR 23407]. In response to a citizen petition (Docket FDA-2012-P-1071), FDA’s 2013 determination (78 FR 13900) confirmed that Geref and Geref Diagnostic were not withdrawn for reasons of safety or effectiveness — a determination that subsequently permitted generic ANDA submissions and supported the compounding pathway [Regulatory document — FDA 78 FR 13900].

EMA never authorized sermorelin in any indication [Regulatory document — EMA central register, no EPAR].

The post-2008 period saw sermorelin re-emerge through 503A compounding pharmacies as an off-label “anti-aging” / “GH-optimization” prescription, despite no FDA approval for any adult indication. This commercial repositioning occurred without new pivotal trials. The December 4, 2024 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting addressed AOD-9604, CJC-1295-related substances, thymosin α-1-related substances, and several other peptides — but did not address sermorelin, because sermorelin already qualifies as a component of a previously FDA-approved drug under §503A; it did not require a bulks-list nomination [Regulatory document — FDA PCAC meeting transcript December 4, 2024; FDA Briefing Document October 29, 2024].

3. Mechanism of Action

3.1 Demonstrated in humans

  • GHRH receptor (GHRHR) agonism. Sermorelin is a full agonist at the human GHRH receptor (class B1 GPCR) on anterior pituitary somatotrophs [Peer-reviewed mechanistic — Mayo 1992 Mol Endocrinol 6:1734; IUPHAR/BPS GtoPdb]. Receptor activation couples via Gαs to adenylate cyclase, increases intracellular cAMP, activates PKA, and promotes both GH1 transcription and acute exocytotic release of stored growth hormone [Peer-reviewed mechanistic — Frohman & Kineman 2002].
  • Acute GH pulse. Intravenous or subcutaneous administration produces a GH peak within 5–15 minutes lasting ~60–120 minutes in healthy adults; plasma half-life of the peptide itself is ~11–12 minutes due to rapid degradation by dipeptidyl peptidase IV (cleaving at Ala²) and serum endopeptidases [Peer-reviewed human study — Thorner 1986 PMID 3097061; Prakash & Goa 1999 PMID 18031173].
  • IGF-1 elevation downstream. Sustained nightly s.c. dosing elevates serum IGF-1 and IGFBP-3 in age-advanced adults within 2 weeks [Peer-reviewed human study — Khorram 1997 PMID 9141536 🔴; Corpas 1992 PMID 1379256].
  • Pulsatility preservation. Because GHRH stimulation is itself modulated by hypothalamic somatostatin and by IGF-1 negative feedback at the pituitary, sermorelin-evoked GH release retains pulsatile architecture and is self-limiting [Peer-reviewed mechanistic — Veldhuis 2004; Frohman & Kineman 2002]. This pharmacology is the basis for the community framing that secretagogues are “physiologic” relative to exogenous somatropin.

3.2 Proposed / preclinical

  • Sleep architecture. Nightly dosing has been reported to amplify nocturnal GH pulses in older adults, with mixed effects on slow-wave sleep [Peer-reviewed human study — Vittone 1997 PMID 9005976]. Direct GHRH-mediated SWS promotion derives primarily from rodent intracerebroventricular infusion data [Peer-reviewed preclinical — Obal & Krueger 2004].
  • Cardioprotection / myocardial repair. Preclinical only: GHRH receptor expression demonstrated on cardiomyocytes; sermorelin and other GHRH agonists reduced infarct scar size in swine and rodent MI models [Peer-reviewed preclinical — Granata 2009; Penna 2013].
  • Immunomodulation. A 16-week sermorelin-analog trial reported lymphocyte subset changes in older adults [Peer-reviewed human study — Khorram, Yeung, Vu & Yen 1997 PMID 9360512 🔴 single research group, same cohort as Khorram 1997 PMID 9141536].

4. Regulatory Status

4.1 Drug-regulatory status

AuthorityStatusIdentifier / Date
FDA (US) — therapeuticApproval withdrawn 2009-06-18; not for safety/efficacy reasonsNDA 020443; 74 FR 23407; 78 FR 13900
FDA (US) — diagnosticApproval withdrawn 2009-06-18; not for safety/efficacy reasonsNDA 019863
FDA 503A bulks listCompoundable under §503A as a component of a previously FDA-approved drug (NDA 020443). Sermorelin was not among the peptides placed in interim Category 2 in September 2023, and was not subject to PCAC vote at the October 29, 2024 or December 4, 2024 meetings (those addressed ipamorelin, ibutamoren, kisspeptin-10, L-theanine, AOD-9604, CJC-1295-related, and thymosin α-1-related substances)FDA media/182088, /183017, /185641, /94155
EMANever approvedEMA central register (no EPAR)
MHRA (UK)No marketing authorization; BNF lists historical Geref but flags discontinuationBNF historical entries
TGA (Australia)Schedule 4 (Prescription Only Medicine) under the Therapeutic Goods (Poisons Standard — October 2025) Instrument 2025 as a peptide hormone analogue (captured by generic peptide-hormone S4 provisions); no specific Appendix D restriction identifiedTGA Poisons Standard October 2025
Health CanadaNo Notice of Compliance / DIN for sermorelin productsHealth Canada Drug Product Database
PMDA (Japan)Not approvedPMDA product list
NMPA (China)Not approvedNMPA register
MFDS (South Korea)Not approvedMFDS register
GRLS (Russia)Not approved as a registered medicinal productGRLS state register
WHO EMLNot listedWHO Essential Medicines List 23rd ed. 2023

4.2 Anti-doping status

  • WADA 2026 Prohibited List, Section S2.2.4 — Growth Hormone Releasing Factors: the list verbatim reads “growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)” [Anti-doping document — WADA 2026 Prohibited List, in force 2026-01-01]. Sermorelin is explicitly named.
  • Status: Prohibited at all times — both in-competition and out-of-competition. All S2 substances are Specified Substances under the 2026 list [Anti-doping document — WADA 2026 Prohibited List].
  • TUE eligibility: Theoretically possible but practically very unlikely; USADA’s published athlete advisory explicitly states a TUE is “highly unlikely” to be approved because sermorelin is not first-line for GHD and approved alternatives (recombinant somatropin) exist, and because the commercial Geref product has been discontinued [Anti-doping document — USADA “What Should Athletes Know About Sermorelin?”].
  • NCAA: Prohibited as a peptide hormone / GH-releasing factor under the NCAA Banned Drug Class “Peptide Hormones, Growth Factors, Related Substances and Mimetics” [NCAA Banned Drug List 2025–26].
  • DoD-OPSS: Sermorelin flagged as a peptide hormone / GH secretagogue prohibited for service members; categorized within the DoD’s “do not use” peptide group [DoD Operation Supplement Safety — peptide hormones list].
  • Global DRO (globaldro.com): Returns sermorelin as Prohibited in- and out-of-competition under WADA S2 — checked 2026-05-15.
  • BSCG: Listed under banned WADA S2 peptide hormones in 2026 reference materials.
  • Detection windows / assays: GHRH(1-29) and synthetic analogues are detectable in serum/urine by targeted LC-HRMS/MS methods developed by WADA-accredited laboratories for the S2.2.4 panel; published methods report detection windows of hours to ~1–2 days after a single s.c. dose, dose-dependent [Peer-reviewed analytical — Thomas 2012 Anal Bioanal Chem; Esposito 2015 Drug Test Anal]. Athletes are additionally subject to indirect detection via the IGF-1 / P-III-NP GH biomarker test, though that test was developed and validated for recombinant GH rather than for GHRH secretagogues specifically.
  • Notable sanctions: No high-profile WADA AAFs publicly attributed to sermorelin specifically; the 2013 Australian Crime Commission report on Organised Crime and Drugs in Sport identified sermorelin among peptides confiscated in performance-enhancement supply chains [Regulatory/intelligence — ACC 2013].

4.3 Last regulatory review

Last regulatory review: 2026-05-15

5. Formulations and Routes

FormulationStatusRoute
Geref® 0.5 mg, 1.0 mg/vial s.c. injection (NDA 020443)Approved 1997-09-26; withdrawn 2009-06-18Subcutaneous, once daily at bedtime
Geref Diagnostic® 0.05 mg/amp (NDA 019863)Approved 1990-12-28; withdrawn 2009-06-18Intravenous bolus, 1 µg/kg single dose
503A compounded sermorelin acetate (lyophilized) — typically 5–15 mg/vial, often co-compounded with ipamorelin or CJC-1295 (e.g., “ipamorelin/sermorelin acetate 15/18 mg vial”)Not FDA-approved as finished product; compoundable under §503A as a component of NDA 020443Subcutaneous
Oral, sublingual, transdermal, intranasal sermorelinInvestigational / not validated — no published PK data demonstrating clinically relevant bioavailabilityVarious

⚠️ The compounded combination preparations (sermorelin + ipamorelin, sermorelin + CJC-1295) have no peer-reviewed efficacy or safety data as fixed combinations; safety is extrapolated from each peptide individually.

6. Preclinical Evidence

  • GHRH receptor pharmacology. Sermorelin retains full intrinsic activity at the cloned human GHRHR (Mayo 1992); minimum effective dose for GH release in rat pituitary cells in vitro ~0.4 × 10⁻¹⁵ M [Peer-reviewed preclinical — Heiman 1985]. Affinity at GHRHR is comparable to native 1-44 GHRH.
  • Rodent GH/IGF-1 stimulation. Repeated s.c. dosing in rats increases pulsatile GH and IGF-1 dose-dependently; effect is abolished in hypophysectomized animals, confirming pituitary site of action [Peer-reviewed preclinical — Walker 1990 Endocrinology 126:1527].
  • Comparative GHRH-analogue pharmacology.
    • Sermorelin (GHRH 1-29 NH₂): half-life ~11–12 min, DPP-IV-susceptible at Ala² [Peer-reviewed — Frohman 1989]
    • Tesamorelin (trans-3-hexenoyl-GHRH(1-44)): N-terminally lipid-modified to resist DPP-IV; half-life ~26–38 min; full-length backbone [Peer-reviewed — Falutz 2007]
    • CJC-1295 (DAC) (D-Ala²-GHRH(1-29) coupled to maleimidopropionyl-Lys³⁰ for albumin binding): half-life ~6–8 days; loss of pulsatility [Peer-reviewed — Teichman 2006]
    • Ipamorelin: pentapeptide GHS-R1a (ghrelin receptor) agonist — different receptor entirely, not a GHRH analogue [Peer-reviewed — Raun 1998]
  • Animal cardiac, neural, and immune models (preclinical only): GHRH agonist signaling has been shown to reduce post-MI scarring in swine, support hippocampal neurogenesis, and modulate thymic output in rodents [Peer-reviewed preclinical — Granata 2009; Banks 2010]. None of these endpoints has been replicated in adequately powered human trials with sermorelin specifically.

7. Clinical Evidence

Cochrane systematic reviews: No Cochrane systematic review specifically on sermorelin in any indication identified as of 2026-05-15 [Cochrane Library search 2026-05-15 — null result]. The closest class-level synthesis remains Liu 2007 (see §7.5).

7.1 Paediatric idiopathic GHD (the on-label FDA indication)

  • Thorner et al. 1996 (PMID 8755644) ⚠️ Serono-funded: Multicenter, open-label trial of once-daily s.c. sermorelin 30 µg/kg at bedtime in prepubertal children with idiopathic GHD. Height velocity increased significantly (approximately from ~4 to ~7–8 cm/year) over 12 months; effect sustained through 36 months in a subset. This was the pivotal supporting study for NDA 020443 [Peer-reviewed human study — Thorner 1996 JCEM 81:1189].
  • Ranke et al. 1986: Established GHRH(1-29)NH₂ as a provocative diagnostic test for GHD in pediatric populations.
  • Prakash & Goa 1999 (PMID 18031173) review: Synthesized the available trial evidence, concluding sermorelin produced catch-up growth in the majority of children with idiopathic (hypothalamic) GHD but was ineffective for pituitary-origin deficiency. Effect on final adult height was not adequately characterized at the time of FDA approval — a gap that was never closed [Peer-reviewed secondary — Prakash & Goa 1999 BioDrugs 12:139].
  • Comparative effect vs somatropin: Recombinant human GH consistently produced larger height-velocity gains than sermorelin in head-to-head and historical comparisons; sermorelin’s clinical utility was limited to a subset of children with intact pituitary GH stores.

7.2 Adult GHD — diagnostic stimulation testing

Sermorelin (1 µg/kg i.v.) was used as a provocative agent, often combined with arginine to improve specificity. The GHRH+arginine test was widely used in the 1990s–2000s before being largely superseded by the insulin tolerance test, glucagon stimulation test, and the FDA-approved macimorelin oral stimulation test (Macrilen®, NDA 205598, approved 2017) [Peer-reviewed clinical — Aimaretti 1998; Garcia 2013]. Geref Diagnostic’s withdrawal in 2009 effectively removed sermorelin from routine diagnostic use in the US.

7.3 Adult longevity / “anti-aging” use (primary optimization-audience indication)

Dedicated human evidence for adult longevity reduces to a small cluster of 1990s trials, primarily from two groups (the Yen / Khorram laboratory at UCSD 🔴 and the Mitchell Harman / Marc Blackman NIA group), plus the Vittone 1997 single-site trial:

  • Corpas et al. 1992 (PMID 1379256) — NIA group: 10 healthy men aged 60–78 vs 9 young controls. GHRH(1-29) 0.5 mg and 1.0 mg s.c. b.i.d. for 14 days each, 14-day washout. Mean 24-h GH, peak amplitude, and IGF-I increased significantly at the higher dose, with values reaching the young-control range. No adverse outcomes over 14 days [Peer-reviewed human study — Corpas 1992 JCEM 75:530].
  • Vittone et al. 1997 (PMID 9005976) — Johns Hopkins / NIA group ⚠️ Serono-supported: Single nightly s.c. GHRH(1-29) in 11 healthy elderly men over 6 weeks. Increased 24-h integrated GH and IGF-1; body composition effects modest; sleep architecture not consistently improved [Peer-reviewed human study — Vittone 1997 Metabolism 46:89].
  • Khorram, Laughlin & Yen 1997 (PMID 9141536) — UCSD 🔴 single research group: Single-blind, randomized, placebo-controlled trial of [Nle²⁷]GHRH(1-29)-NH₂ 10 µg/kg s.c. nightly for 16 weeks in 10 women and 9 men aged 55–71 (after a 4-week saline run-in). Outcomes: 12-h nocturnal GH integrated levels increased in both sexes; IGF-1 and IGFBP-3 rose within 2 weeks; skin thickness increased in both sexes; lean body mass increased by 1.26 kg in men only; insulin sensitivity, well-being, and libido improved in men only; sleep quality unchanged; transient hyperlipidemia was the only adverse event noted. The trial used the [Nle²⁷] analogue rather than unmodified sermorelin but is routinely cited as sermorelin-class evidence. ⚠️ NIH-funded (R01-AG-10979) [Peer-reviewed human study — Khorram 1997 JCEM 82:1472].
  • Khorram, Yeung, Vu & Yen 1997 (PMID 9360512) — UCSD 🔴 same group, same cohort: Companion publication reporting lymphocyte/immune readouts from the same 16-week trial. Reported increases in T-cell subsets and NK-cell activity; no independent replication has been published [Peer-reviewed human study].
  • Veldhuis et al. 2004 (JCEM): Sustained twice-daily GHRH stimulation in middle-aged and older adults documented preservation of GH pulsatility under chronic GHRH exposure — a mechanistic confirmation rather than a longevity-outcome study [Peer-reviewed human study].

Critical gap: No multi-center, adequately powered, placebo-controlled RCT of sermorelin in healthy older adults has been published since approximately 1997. No trial has measured longevity, mortality, frailty, or functional outcomes as primary endpoints. ClinicalTrials.gov queries for “sermorelin” return a small number of mechanistic / diagnostic studies with no large adult longevity RCTs registered or completed.

7.4 HIV-associated lipodystrophy

There are no published Phase 2/3 sermorelin trials in HIV-associated lipodystrophy. The HIV-lipodystrophy indication was developed and approved for tesamorelin (Egrifta®, NDA 022505, FDA-approved 2010-11-10), not sermorelin [Regulatory document — FDA NDA 022505; Peer-reviewed — Falutz 2007 NEJM 357:2359; Stanley 2014]. Tesamorelin’s longer half-life and full-length GHRH backbone supported clinically meaningful visceral adipose tissue reduction; comparable data do not exist for sermorelin.

7.5 Disputed Claims — Rudman 1990 vs Liu 2007 (and the sermorelin question)

Position A — Rudman 1990 and the “GH anti-aging” hypothesis lineage. Daniel Rudman and colleagues at the Medical College of Wisconsin reported in the New England Journal of Medicine (1990 Jul 5;323:1–6; PMID 2355952) that 6 months of biosynthetic human growth hormone (0.03 mg/kg s.c. three times weekly, ~0.19 mg/kg/week) in 12 healthy men aged 61–81 with low baseline IGF-1 produced +4.7 kg lean body mass, −3.5 kg adipose mass, +0.02 g/cm² lumbar bone density, and increased skin thickness, vs no treatment in 9 controls. The paper became the founding citation of the “GH-as-anti-aging” thesis and was widely propagated by anti-aging marketing in the subsequent two decades [Peer-reviewed human study — Rudman 1990 PMID 2355952]. Funding: NIH and the VA Medical Research Service.

Sermorelin-specific extension of Position A. Khorram 1997 (PMID 9141536), Vittone 1997 (PMID 9005976), and Corpas 1992 (PMID 1379256) reproduced GH-axis activation and IGF-1 elevation in older adults using GHRH(1-29) rather than recombinant GH, providing the mechanistic basis cited by sermorelin proponents that the same body-composition signal might be achievable via secretagogue stimulation while preserving pulsatility. However, the body-composition effect sizes in Khorram 1997 were smaller than Rudman 1990, present in men only, and no longevity, frailty, mortality, fracture, or cognition endpoints were measured.

Position B — Liu 2007 systematic review. Liu, Bravata, Olkin, Nayak, Roberts, Garber and Hoffman (Stanford), in Annals of Internal Medicine (2007 Jan 16;146:104–115; PMID 17227934), conducted a systematic review and meta-analysis of 31 articles (18 unique controlled studies, 220 participants, ~107 patient-years) of GH administration in the healthy elderly. Findings: GH treatment produced small changes in body composition (mean fat mass change −2.1 kg; lean body mass change +2.1 kg) but no improvement in bone density, lipid profile, or other clinically meaningful outcomes, and was associated with significantly increased rates of soft-tissue edema, arthralgia, carpal tunnel syndrome, gynecomastia, and a trend toward incident impaired fasting glucose / type 2 diabetes. The authors concluded GH “cannot be recommended as an anti-aging therapy.” Funding: VA Health Services Research and Development Service; no industry funding declared. The accompanying editorial (Perls, Annals 2007) and a subsequent commentary (Barkan, Nat Clin Pract Endocrinol Metab 2007 PMID 17534272) endorsed the conclusion.

Sermorelin-specific consideration in Position B. Liu 2007 was a GH-class analysis and did not isolate GHRH-secretagogue trials. The Khorram and Vittone sermorelin/GHRH(1-29) trials are smaller (n<25 each), single-sex-stratified, and predominantly from one research group (Khorram 🔴), so their negative-evidence weight against Position A is weaker than the Liu meta-analysis but their positive-evidence weight is correspondingly weaker than Rudman 1990. The Endocrine Society’s 2023 Hormones and Aging Scientific Statement (Verbalis et al.) maintained that no GH secretagogue is established as an anti-aging therapy [Peer-reviewed — Verbalis 2023].

Voice rule per Section 7.5 protocol: Both sides are presented without resolution. The Rudman 1990 paper has not been retracted (verified PubMed 2355952 status 2026-05-15). The Liu 2007 paper has not been retracted (verified PubMed 17227934 status 2026-05-15). Khorram 1997 (PMIDs 9141536, 9360512), Vittone 1997 (PMID 9005976), and Corpas 1992 (PMID 1379256) are likewise not retracted. The 1990 NEJM editorial (Vance, “Growth Hormone for the Elderly?”, NEJM 323:52) noted from publication that the Rudman dose was approximately twice the dose used in adults with documented GHD and questioned generalizability; this caution was rarely reproduced in subsequent secondary literature citing Rudman.

7.6 Sleep, cognitive, and body-composition outcomes in older adults

  • Mixed sleep data: Vittone 1997 reported modest amplification of nocturnal GH pulses; Khorram 1997 reported subjective sleep quality “unaffected” by questionnaire.
  • No adequately powered RCT of sermorelin on cognitive outcomes has been published.
  • Body-composition signal is small (lean mass ~1–1.3 kg in men) and sex-dependent.

7B. Community Evidence Layer

Driving subcommunity. Anti-aging and longevity-adjacent telehealth clinics are the largest channel (Defy Medical, Marek Health, Eden, HydraMed, Gameday, Sermorelin.com, BodyLogicMD-style chains), with secondary adoption by mainstream biohacker / longevity media (Ben Greenfield, Jay Campbell, Andrew Huberman, Joe Rogan / Flagrant 2, Peter Attia indirectly via Derek/MPMD). The bodybuilding / PED-forum channel (MESO-Rx, EliteFitness, Meso-Morph) discusses sermorelin but largely as a comparator to the CJC-1295 + Ipamorelin stack rather than as a preferred protocol.

Adoption lineage. Three waves. Wave 1 (mid-2000s → 2010s): anti-aging clinics absorb sermorelin immediately after the 2008 Geref commercial withdrawal — Defy Medical’s own resource material describes prescribers having “4 years of observing patients taking Sermorelin” in copy on site since the early 2010s. Wave 2 (2020–2024): longevity-curious mainstream pickup via Ben Greenfield’s peptide articles, Jay Campbell’s Peptide Optimization Course, and Joe Rogan / Huberman Lab mentions in 2023. Andrew Huberman’s April 2024 “Benefits & Risks of Peptide Therapeutics” episode is the single most-cited mainstream reference point. Wave 3 (2024–2025 post-PCAC): consolidation in the telehealth-wellness ecosystem after the December 2024 PCAC vote removed CJC-1295, ipamorelin, BPC-157, AOD-9604 and others from 503A compounding access — sermorelin survived on the “component of a previously FDA-approved drug” pathway and became, by elimination, the only legally compoundable GHRH-axis peptide in the US.

Current trajectory. Rising in mainstream telehealth; declining in the bodybuilding-research community as users migrate to tesamorelin or to grey-market CJC/ipamorelin sourcing.

Canonical clinic protocol — sourced. “200–300 mcg subcutaneous, before bed, 5 nights per week, on an empty stomach” is reproduced near-verbatim across Defy Medical, Olympia Pharmaceuticals, Eden (tryeden.com), HydraMed, Sermorelin.com, Swolverine, Atlas Men’s Health, Gemini Health & Wellness, Alpha Rejuvenation, AlphaMD, Elite Health Center NYC, PeptideDeck, Sermorelin.com, and Strive Pharmacy. Origin: the convention traces to Defy Medical and the Tampa anti-aging cluster (Defy, PRAMAH), then propagated through Empower / Olympia / Hallandale compounding-pharmacy dosing charts in the 2015–2022 window before becoming the default starting protocol for the 2022–2024 telehealth wave (Eden, HydraMed, Marek, Gameday). PRAMAH separately cites a higher-end physician protocol of “200–1000 mcg, 1–3 daily doses, or 10 mcg/kg once daily before bed” — reflecting the original 10 µg/kg pediatric-derived dose closer to what Khorram 1997 used.

Cycling vs continuous use — split. Anti-aging clinics (Defy, Eden, Sermorelin.com) lean toward continuous nightly dosing with IGF-1 titration. Bodybuilding-derived sources (Swolverine, Ben Greenfield, MESO-Rx) lean toward “8–16 weeks on, 1–2 months off” cycling with explicit reference to pituitary desensitization. The split is largely cultural: clinics monetize continuous subscriptions; the PED-derived community defaults to cycling. Andrew Huberman’s reported pattern (1–2 nights/week, eventually mostly discontinued) is a third position — neither rigid cycling nor continuous use, but episodic.

Most commonly claimed effects (frequency labels are derived from the cross-source pass):

  • Improved sleep / deeper slow-wave sleep — widespread; the dominant first-month effect across clinic, podcast, forum, and vendor sources. Defy: “patients usually report improved sleep within the first few weeks.” Huberman Lab April 2024: “very deep, very robust” in the early part of the night.
  • Increased energy / mood — common; usually framed downstream of sleep.
  • Body recomposition (fat loss + lean mass gain) — common, slow-onset; universally described as a 3–6 month effect. Khorram 1997 is the canonical cite for ≈1.26 kg lean mass gain in men over 16 weeks.
  • Vivid dreams — common; treated as a marker that the drug is “working” on slow-wave architecture.
  • Skin quality / thickness — common in clinic marketing, weaker in user reports (the disjunction itself is a community talking point).
  • Recovery from training / injury — common in Greenfield, Jay Campbell, MESO-Rx threads.
  • Libido / sexual function — occasional.
  • IGF-1 elevation — universally claimed, frequency debated; multiple MESO-Rx and r/Peptides-adjacent threads (referenced via third-party summaries) report disappointing IGF-1 bloodwork at clinic 200–300 mcg doses.

Most commonly reported side effects:

  • Injection-site reactions — widespread; rotating sites is the standard mitigation.
  • Flushing / warm sensation, especially first dose — common; commenter on Ben Greenfield article: “Are you getting hot flashes too? It means it’s working… Dies down after an hour.”
  • Drowsiness post-injection — common and usually desired (with bedtime dosing).
  • Headache, especially first 1–2 weeks — common.
  • Wakefulness in the second half of the night — single named-figure report (Huberman): “I would wake up wide awake or I would sleep till morning” — Huberman’s cited reason for scaling back.
  • Water retention — occasional, consistently described as milder than synthetic HGH.
  • Carpal tunnel / numbness — rare; conspicuously less reported than for HGH or for high-dose CJC-1295 + Ipamorelin stacks.

Community dissent — eight named splits (from Pass 2):

  1. “Clinic doses are subtherapeutic.” Dominant on MESO-Rx; the “Starting Sermorelin – Rx Dosing Seems Low” thread (2024) is archetypal — clinical studies used ~10 µg/kg (~800 mcg for an 80 kg adult), but clinics prescribe 200–300 mcg flat.
  2. “Sermorelin vs CJC-1295 + Ipamorelin.” HealingMaps 2026: “Sermorelin alone is the simpler, gentler option… CJC-1295 stacked with Ipamorelin is the stronger, more popular modern option.” Forum view: sermorelin is obsolete except for the regulatory reason that it remains compoundable.
  3. “Did the FDA ban sermorelin in Dec 2024?” Lay press and some clinics (Hone Health, Vitalize Medical) frame the PCAC vote as a sermorelin ban; the Frier Levitt regulatory analysis (April 2025) and Strive Pharmacy’s 2025 practitioner guide explicitly state the opposite — sermorelin survived because Geref was an FDA-approved drug withdrawn for non-safety reasons.
  4. “Pharma protection or legitimate safety?” Vitalize Medical invokes “Big Pharma” framing; Frier Levitt cites the (then-recent) HHS rhetoric promising to reverse “aggressive suppression of psychedelics, peptides, stem cells…”
  5. “Tachyphylaxis — real or overstated?” Swolverine, MESO-Rx, and bodybuilding sources treat it as established (driving cycling protocols); clinic literature (Defy, Sermorelin.com) implicitly disputes it (promoting continuous use with titration).
  6. “Pre-bed timing — doctrine or convention?” Most clinics and podcasts treat pre-bed as physiologically necessary; a minority forum view (cited in PRAMAH, PeptideDeck) holds the short half-life means timing matters less than total exposure.
  7. “Compounded vs research-grade sourcing.” Clinic-prescribed Empower / Tailor Made / Hallandale / Olympia compounded product is the community quality reference; research-peptide vendor product is a function of which third-party lab certificate (Janoshik being the de facto standard) the vendor publishes.
  8. “Is elevating GH/IGF-1 in over-40s actually good for longevity?” The deepest unresolved tension. Anti-aging clinics treat it as self-evidently good. Peter Attia and Derek / MPMD on The Drive #274 are notably restrained. Ben Greenfield’s own articles include “Should You Get Growth Hormone Injections (And Will GH or IGF-1 Increase Your Cancer Risk)?” — even pro-peptide voices acknowledge the tension. The longevity sub-community (Sinclair-adjacent, D’Agostino-adjacent) is the most skeptical; the anti-aging clinic ecosystem is the most enthusiastic. Sermorelin’s defenders argue the negative-feedback mechanism (somatostatin still active) prevents the supraphysiologic IGF-1 elevations exogenous HGH produces.

Stack patterns — sourced:

  • Sermorelin + TRT. The most common real-world stack in anti-aging telehealth clinics (Defy, Marek, Gameday, BodyLogicMD, Cenegenics).
  • Sermorelin + Ipamorelin (without CJC). Common entry-level clinic stack exploiting the GHRH × GHS-R dual-pathway synergy; complicated post-2024 by ipamorelin’s compounding-access loss.
  • Sermorelin + CJC-1295 (no DAC) + Ipamorelin — the “trinity.” Often cited as canonical; bodybuilding-community practice replaces pure sermorelin with Mod GRF 1-29. Ben Greenfield’s growth-hormone-stacks article lays out the canonical version (CJC no DAC + Ipamorelin 200 mcg each, AM, 5/2, 8–10 weeks on/off).
  • Sermorelin + MK-677. Documented on Meso-Morph stacker threads; community caution on combined appetite/water retention.
  • Sermorelin + BPC-157 / TB-500. Recovery / tissue-repair angle; now complicated by BPC-157 and TB-500 losing 503A access.
  • Sermorelin + tirzepatide / semaglutide. Newest pattern, post-2023. Telehealth clinics (Marek Health, Defy) pair sermorelin with GLP-1 agonists to preserve lean mass during GLP-1-driven weight loss. Strive Pharmacy’s 2025 practitioner guide leads with this framing.

Vendor / supply. Telehealth clinic pricing 2024–2026: $199–$450/month typical (HydraMed $199–$275; Eden / Sermorelin.com / Marek / Gameday $200–$400; Defy $300–$450 with separate consult fees). Compounding pharmacies behind the clinics: Empower, Tailor Made Compounding, Hallandale, Olympia, Strive — all currently compounding sermorelin acetate. Research-peptide vendor channel: Peptide Sciences ($30–$80 / 2–5 mg vial reference pricing), Peptide Partners, BiotechPeptides, Real Peptides, Ascension, Limitless Life Nootropics; PeptideDeck flags sub-$10 vials as quality red flags. Janoshik Analytical is the community-default third-party reference lab. The post-2024 enforcement environment has consolidated US buyer flow toward sermorelin via clinic compounding rather than driven offshore sourcing — distinguishing sermorelin’s vendor pattern from CJC-1295 / ipamorelin / BPC-157, where domestic compounding access is now blocked.

Community Score (Pass 2, transparent breakdown):

SubscoreScore / MaxRationale
Usage volume21 / 25Extremely high search and discussion volume; mainstream podcast coverage; dozens of telehealth clinics carry it; >10 research-peptide vendors stock it. Slight haircut because it is mostly framed as a “gateway” peptide users move off of.
Protocol codification23 / 25The most codified protocol of any GH-axis peptide in the optimization space. “200–300 mcg, subcutaneous, before bed, 5 nights/week” is near-monolithic. Minor variation only in cycling.
Reported effect consistency17 / 25High consistency on sleep and energy; moderate on body recomp (delayed onset, individual variability); weak on skin and libido (heavy in clinic marketing, thinner in user reports); meaningful internal disagreement on whether IGF-1 actually moves at clinic doses keeps this from scoring higher.
Time in circulation24 / 25Originally FDA-approved 1997; anti-aging clinic use from mid-2000s; bodybuilding forums from early 2010s; mainstream podcast / biohacker awareness from 2020s. Approaching three decades in some form, ≈20 years in the optimization community.
Total85 / 100Tier A (75–89)

Substantive limitations disclosure (from Pass 2). Direct Reddit thread-level retrieval (r/Peptides, r/PeptideUmbrella, r/SteroidsHGH, r/longevity, r/Nootropics, r/Biohackers, r/Testosterone, r/trt, r/AnabolicSteroids, r/PEDs) returned no usable results during this pass. Reddit-specific dose, side-effect, and tachyphylaxis claims are sourced indirectly through clinic write-ups, vendor pages, podcast transcripts, and forum aggregators (MESO-Rx, Meso-Morph), and are described as community-reported rather than tied to specific Reddit permalinks or vote counts. Specific MESO-Rx and EliteFitness archive threads (e.g., “Starting Sermorelin – Rx Dosing Seems Low”) were retrievable via search snippets but not at full-thread named-source resolution. The specific Joe Rogan / Flagrant 2 episode in which Andrew Huberman discussed sermorelin is referenced via a third-party YouTube summary rather than the original episode transcript. Jay Campbell’s Peptide Optimization Course internal protocols are referenced through Ben Greenfield podcast appearances rather than retrieved directly. Telegram and Discord peptide-community discussion was not retrieved. Cenegenics and BodyLogicMD current sermorelin protocol pages are referenced via secondary sources. Peter Attia’s most explicit on-record sermorelin commentary could not be located at named-source resolution; his general skepticism toward elevating IGF-1 in adults is documented across cross-podcast syntheses.

8. Safety Profile

Common adverse events (from Geref labelling and the 1990s trial corpus):

  • Injection-site reactions (pain, erythema, swelling, pruritus, induration): most common AE in pediatric and adult sermorelin studies.
  • Facial flushing, headache, dysphagia / dysgeusia (altered taste — a sermorelin-class AE reported with i.v. dosing during diagnostic testing).
  • Transient hyperlipidemia (Khorram 1997).
  • Hypersensitivity reactions reported rarely.

Class concerns (theoretical or extrapolated from GH replacement):

  • Glucose intolerance / insulin resistance: Long-term sermorelin data are insufficient to characterize this signal. Liu 2007 documented increased impaired fasting glucose with GH itself; Khorram 1997 (n=19, 16 weeks) reported improved insulin sensitivity in men. The pulsatility-preserving mechanism is theorized to attenuate the signal vs supraphysiologic GH, but this is not established by adequately powered trials.
  • Neoplasia (theoretical): Sustained IGF-1 elevation has been hypothesized to influence cancer risk; no sermorelin-specific long-term cancer surveillance data exist. Standard contraindication: known active malignancy.
  • Fluid retention / arthralgia / carpal tunnel syndrome: Hallmark GH replacement AEs; sermorelin trial cohorts are too small and too short to characterize incidence reliably.
  • Sermorelin-specific Geref label warnings (historical): caution in epilepsy, untreated hypothyroidism, obesity, hyperglycemia, elevated plasma fatty acids.

Trial exclusions (across the sermorelin RCT corpus): history of malignancy, diabetes, uncontrolled hypertension, severe hepatic / renal impairment, active pituitary disease, pregnancy.

Special populations: No adequate data in pregnancy or lactation; no pediatric safety beyond the GHD indication; no formal geriatric studies beyond the 1990s small trials.

Retraction status (verified 2026-05-15): No retractions identified for Rudman 1990 (PMID 2355952), Khorram 1997 (PMIDs 9141536, 9360512), Vittone 1997 (PMID 9005976), Corpas 1992 (PMID 1379256), Liu 2007 (PMID 17227934), Thorner 1996 (PMID 8755644), Falutz 2007 (PMID 18057338), or Stanley 2014.

9. Drug Interactions

  • Glucocorticoids: Supraphysiologic glucocorticoid exposure suppresses GH release at multiple levels; concurrent use blunts sermorelin response [Peer-reviewed mechanistic — Giustina & Veldhuis 1998].
  • Somatostatin and somatostatin analogues (octreotide, lanreotide): Pharmacodynamic antagonism — somatostatin directly inhibits somatotroph GH release; concurrent administration blocks sermorelin’s effect [Peer-reviewed — Pellegrini 2018].
  • Dopamine, L-DOPA, clonidine: Modulate hypothalamic GHRH / SRIF balance and can alter the sermorelin GH response in diagnostic settings.
  • Levothyroxine and thyroid status: Hypothyroidism blunts GH response; thyroid status should be replete for diagnostic interpretation (Geref label).
  • Insulin / antihyperglycemics: Theoretical antagonism due to GH-induced insulin resistance; clinical significance with sermorelin doses is uncharacterized.
  • Sex steroids: Estrogens generally enhance pituitary GH responsiveness to GHRH; testosterone modulates the IGF-1 response; these interactions inform the sex-dependent body-composition outcomes in Khorram 1997.

10. Research Gaps

  1. No Cochrane systematic review specifically on sermorelin in any indication.
  2. No adequately powered RCT of sermorelin in healthy older adults since Khorram 1997; no longevity, frailty, mortality, fracture, dementia, or cardiovascular endpoint trials.
  3. No head-to-head trial of sermorelin versus tesamorelin, CJC-1295 (with or without DAC), ipamorelin, or macimorelin in any indication.
  4. No long-term (>1 year) cancer surveillance data in adult sermorelin users despite widespread compounded use.
  5. No defined optimal “longevity” dose. The 10 µg/kg nightly dose used in Khorram 1997 has no FDA imprimatur and was not optimized via dose-finding; the 200–300 mcg clinic standard has no controlled-trial validation.
  6. No peer-reviewed data on the widely compounded sermorelin + ipamorelin or sermorelin + CJC-1295 combinations — safety and efficacy of co-administration are extrapolated, not measured.
  7. No defined final-adult-height outcome data even for the original pediatric GHD indication (Prakash & Goa 1999 flagged this gap at FDA approval; never closed).
  8. No published evidence of efficacy via oral, sublingual, transdermal, or intranasal routes despite commercial offering of such formulations through 503A pharmacies.
  9. No published RCT on cognitive or sleep architecture outcomes beyond small 1990s mechanistic readouts.
  10. No GH biomarker test validation data for sermorelin specifically in anti-doping detection (vs the IGF-1 / P-III-NP isoform tests for recombinant GH).
  11. No published characterisation of whether community-reported tachyphylaxis is dose-related, time-related, or an artefact of confounded clinic protocols.

11. Bottom-Line Encyclopedia Note

Sermorelin is a 29-amino-acid GHRH analogue (GHRH(1-29)-NH₂) that was FDA-approved as Geref® for paediatric idiopathic growth hormone deficiency (NDA 020443, 1997) and as Geref Diagnostic® for GH-stimulation testing (NDA 019863, 1990); both were commercially withdrawn by EMD Serono in 2009 (74 FR 23407) with FDA confirming the withdrawal was not for safety or effectiveness reasons (78 FR 13900, 2013). Sermorelin remains accessible in the United States through 503A compounding pharmacies as a component of a previously approved drug — and post-December-2024 PCAC, is one of the very few peptide GH-axis options still domestically compoundable. No adult longevity, anti-aging, or performance indication has ever been FDA-approved. The supporting human evidence for adult use is limited to a small 1990s trial cluster (Corpas 1992; Vittone 1997; Khorram 1997) demonstrating GH/IGF-1 elevation and modest, sex-dependent body-composition changes; no subsequent adequately powered randomized trial has been published. The class-level Liu 2007 Annals of Internal Medicine systematic review concluded GH did not produce clinically meaningful benefits in healthy elderly adults and increased adverse events. Sermorelin is explicitly named on the 2026 WADA Prohibited List S2.2.4 and is prohibited in- and out-of-competition. Community Score 85 (A) reflects ~20 years of codified clinic protocol; Science Score 16 (C) reflects the absence of modern controlled trial validation.

11B. Gap Analysis — Where Science and Community Diverge

Sermorelin sits in the High Community + Low-to-Mid Science cell of the gap pattern matrix. The Pass 2 catalog assigns Community A/85; the Pass 1 catalog assigns Science C/16 for the adult longevity indication. The relevant subclassification is not “untested” (as with BPC-157 D/A, where no human controlled trial exists) and not “tested negative” (as with niacin in statin add-on) — sermorelin is “tested at higher doses than the community uses, with class-level meta-analytic skepticism, and not refreshed since 1997.” It is the only entry in the catalog so far where a clinic-protocol dose is meaningfully below the dose that produced the cited research effects.

TopicScience layerCommunity layerGap
Sleep / deep sleep amplification — the dominant community claimLimited human RCT data: Vittone 1997 reports modest nocturnal GH-pulse amplification; subjective sleep quality “unaffected” in Khorram 1997. No SWS-architecture RCT.Widespread and consistent report across clinic, podcast, forum, and vendor sources. Huberman Lab April 2024: “very deep, very robust” deep sleep early-night.🟡 Untested at adequate power. The community signal is internally consistent and biologically plausible (nocturnal GH pulse synchrony) but has never been adequately tested with modern sleep-architecture endpoints.
IGF-1 elevation — universally claimedTested positive: Khorram 1997 reports IGF-1 and IGFBP-3 rise within 2 weeks at 10 µg/kg 🔴; Corpas 1992 confirms in 14-day NIA work.Universally claimed by clinics; multiple community threads (MESO-Rx, r/Peptides-adjacent) report no meaningful IGF-1 movement at clinic-prescribed 200–300 mcg.🔴 Dose-disconnect. Trials used ~800 mcg-equivalent in an 80 kg adult; clinics prescribe 200–300 mcg flat. The community split on whether IGF-1 actually moves is, on the available data, the predictable consequence of the dose gap.
Body composition (lean mass +, fat mass −)Tested positive but small: ~1.26 kg lean mass gain in men only over 16 weeks (Khorram 1997 🔴 single group). Liu 2007 class-level: small body-composition effects without clinically meaningful downstream benefit.Common claim; described as 3–6 month onset. Defy: “after 3–6 months… noticeable or significant body changes.”🟡 Sex-dependent, single-group dependency 🔴, smaller than community marketing implies. No replication since 1997.
Skin thickness / qualityKhorram 1997: increased skin thickness in both sexes 🔴.Heavy in clinic marketing (Defy, Atlas, Gemini, Dr. Hegedosh); thinner in user reports — the disjunction is a community talking point.🟡 Tested-positive in one trial, under-reported as a user outcome. Single-group dependency unresolved.
Libido / sexual functionKhorram 1997: improved in men only 🔴.Occasional in clinic marketing; rarely volunteered in user reports.🟡 Tested-positive once, sex-restricted, not a salient user-reported effect.
Anti-aging / longevityLiu 2007 negative class-level meta-analysis (GH in healthy elderly); Endocrine Society 2023 Hormones and Aging Scientific Statement maintains no GH secretagogue is established as anti-aging therapy. Rudman 1990 vs Liu 2007 is unresolved in §7.5.Anti-aging clinic ecosystem treats GH/IGF-1 restoration as self-evidently good. Longevity sub-community (Sinclair-, D’Agostino-adjacent), Peter Attia, Derek/MPMD are notably restrained.🔴 Direct class-level meta-analytic conflict with the dominant clinic framing. The community channel is internally split, with anti-aging clinics on one side and the longevity-research-adjacent voices on the other.
Tachyphylaxis / pituitary desensitizationNo adequately powered evidence. Mechanistically plausible at supraphysiologic doses; less plausible at pulsatility-preserving doses.Treated as established by bodybuilding-derived sources (driving 8–16 weeks on / 1–2 months off cycling); implicitly disputed by clinic literature (continuous use with titration).🟡 Community-internal split, science silent.
Sermorelin + ipamorelin / + CJC-1295 fixed combinationsNo peer-reviewed efficacy or safety data on the fixed combinations. Safety is extrapolated from each peptide individually.Common compounded combination products; widely prescribed; canonical “trinity” framing.🔴 Community uses combinations as a standard while no controlled data on those combinations exist.
Sermorelin’s regulatory status after Dec-2024 PCACFrier Levitt (April 2025) and FDA briefing documents are explicit: sermorelin remains compoundable under §503A as a component of a previously FDA-approved drug; it was not affected by the December 2024 PCAC vote.Lay press and some clinics (Hone Health, Vitalize Medical) framed the vote as “sermorelin banned”; better-informed clinics (Strive, Defy) explicitly market sermorelin as “the GH-axis peptide that survived.”🟡 Confusion in lay-press / Tier-2 clinic framing; regulatory specialists and major prescribers have the operational reality correct.
Class-comparator positioning vs tesamorelin and CJC-1295Tesamorelin (Egrifta, NDA 022505) has a positive Phase 3 in HIV lipodystrophy and a longer half-life. CJC-1295 with DAC has a multi-day half-life but lost compounding access in 2024 and has no Phase 3 data.Community framing largely treats sermorelin as the obsolete parent — “same molecule, longer half-life” arguments propagate widely on MESO-Rx and MPMD-adjacent voices.🟢 Aligned. Both layers concur that within the GHRH-analogue class, sermorelin is the lowest-potency, shortest-half-life option with the weakest modern trial base — but the only one currently compoundable in the US.

Net characterisation. Sermorelin’s gap is the cleanest example in this encyclopedia of a peptide where community circulation has continued for 20 years on a regulatory-pedigree foundation that the modern trial base has not refreshed. The supporting human evidence is real but small, sex-restricted, single-group-dependent 🔴 for the body-composition signal, and tested at doses 3–4× higher than the clinic standard. The most consequential reader takeaway is that “FDA-approved” language used in sermorelin marketing refers to a 1997 paediatric GHD approval that was withdrawn in 2009; it does not refer to any adult longevity or anti-aging indication and never did.

This is not a “community ahead of science” pattern in the BPC-157 sense (where no controlled human evidence exists). It is closer to “science evolved past the molecule”: the trial axis moved on to tesamorelin (positive Phase 3 in HIV lipodystrophy), then to CJC-1295 (longer half-life), then to the GH-secretagogue ghrelin-receptor agonists (ipamorelin, ibutamoren) — leaving sermorelin behind in the 1990s-trial cluster, while the community channel adopted sermorelin in the 2000s and kept it on the strength of the FDA-approved-historical-pedigree positioning that no other GHRH analogue can match.

12. Three Paths

Definition, not prescription. The reader chooses the bar; the monograph names where the molecule currently sits relative to each.

Conservative path. Defined as engaging only after (a) peer-reviewed publication of an adequately powered, multicenter, placebo-controlled RCT of sermorelin in healthy adult populations with functional or longevity endpoints, (b) marketing authorisation for an adult indication in a major jurisdiction (FDA, EMA, MHRA, PMDA, TGA, Health Canada), (c) independent replication of the Khorram 1997 body-composition / immune findings outside the UCSD group 🔴, or (d) a positive Cochrane systematic review of GHRH-analogue use in healthy adults. None of these gates is currently met. Sermorelin does not meet the conservative bar for adult longevity use. The conservative path collapses to “not currently engaging.”

Moderate path — physician-supervised, IGF-1-titrated, clinic dose. Defined as engaging through a licensed prescriber using 503A compounded sermorelin at the canonical clinic protocol (200–300 mcg s.c. nightly, 5 nights/week, pre-bed, on empty stomach) with: baseline bloodwork (IGF-1, fasting glucose, HbA1c, lipid panel, CBC, comprehensive metabolic panel, prostate-specific antigen in men); on-cycle monitoring at 8–12 weeks (IGF-1 most importantly, with target in upper-quartile of age-adjusted range rather than youthful elevation); awareness that clinic doses are 3–4× below the doses that drove the supporting research and that IGF-1 movement may be modest or absent; supply through an established compounding pharmacy (Empower, Tailor Made, Hallandale, Olympia, Strive) rather than research-chemical channels; cycling consideration if no signal at 12 weeks. Drug-testing exposure: the moderate path collapses to the conservative path for any athlete subject to WADA, NCAA, USADA, or DoD-OPSS jurisdiction — sermorelin is explicitly named on the WADA 2026 List, S2.2.4, and a TUE is “highly unlikely” per USADA.

High-tolerance path — community mitigation stack. Defined as acknowledging (a) no conservative gate is met, (b) the clinic protocol uses a dose below the research dose, (c) the supporting research is small and dated, (d) the class-level Liu 2007 meta-analysis was negative, (e) the canonical community combinations (sermorelin + ipamorelin, sermorelin + CJC-1295) have no controlled-trial safety or efficacy data, and (f) drug-testing exposure is absolute. The community mitigation stack documented in Pass 2: third-party COA verification (Janoshik or equivalent) on research-chemical sourcing; titrating from below the clinic standard (start 100–200 mcg) rather than at the headline dose; structured bloodwork at baseline and 8–12 weeks; awareness that the body-composition signal is sex-dependent and slow-onset; avoidance of sermorelin + ipamorelin or sermorelin + CJC-1295 fixed combinations in the absence of controlled-trial data; physician-monitoring dialogue even where the physician has not prescribed.

The “FDA-approved” framing in sermorelin clinic and vendor copy carries an asterisk that no path can erase: the 1997 approval was for paediatric GHD, was withdrawn in 2009, and was never refreshed for any adult indication. The compounding pathway is real and currently legal in the US; the indication being treated is, in every adult longevity context, off-label by construction.

13. Key References

Science (Pass 1 layer)

Regulatory documents

  • FDA NDA 020443 — Geref (sermorelin acetate) 0.5 mg, 1.0 mg/vial s.c. Approved 1997-09-26 [Regulatory — Drugs@FDA]
  • FDA NDA 019863 — Geref Diagnostic (sermorelin acetate) 0.05 mg/amp i.v. Approved 1990-12-28 [Regulatory — Drugs@FDA]
  • FDA Federal Register 74 FR 23407 (2009-05-19) — Withdrawal of approval of NDAs 019863 and 020443, effective 2009-06-18 [Regulatory]
  • FDA Federal Register 78 FR 13900 (2013-03-04; document 2013-04827) — Determination that GEREF was not withdrawn for reasons of safety or effectiveness [Regulatory]
  • FDA Briefing Document, PCAC Meeting October 29, 2024 (FDA media/182088) [Regulatory]
  • FDA PCAC Meeting Transcript December 4, 2024 (FDA media/185641) [Regulatory]
  • FDA Bulk Drug Substances Used in Compounding Under §503A list (FDA media/94155, dated 2024-09-27) [Regulatory]
  • TGA Therapeutic Goods (Poisons Standard — October 2025) Instrument 2025 [Regulatory]

Anti-doping documents

  • WADA 2026 Prohibited List, Section S2.2.4 — explicit naming of sermorelin (effective 2026-01-01) [Anti-doping]
  • USADA Athlete Advisory “What Should Athletes Know About Sermorelin?” [Anti-doping]
  • Global DRO sermorelin record — checked 2026-05-15 [Anti-doping]
  • NCAA 2025–26 Banned Drug Class List — Peptide Hormones, Growth Factors, Related Substances and Mimetics [Anti-doping]
  • DoD Operation Supplement Safety — Peptide hormones advisory [Anti-doping]

Peer-reviewed human studies

  • Rudman D, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323:1–6. PMID 2355952
  • Vance ML. Growth hormone for the elderly? N Engl J Med 1990;323:52–4. PMID 2355957 [Editorial]
  • Corpas E, et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and IGF-I levels in old men. JCEM 1992;75:530–5. PMID 1379256
  • Thorner M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. JCEM 1996;81:1189–96. PMID 8755644 ⚠️
  • Vittone J, et al. Effects of single nightly injections of GHRH 1-29 in healthy elderly men. Metabolism 1997;46:89–96. PMID 9005976 ⚠️
  • Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]GHRH(1-29)-NH2 in age-advanced men and women. JCEM 1997;82:1472–9. PMID 9141536 🔴
  • Khorram O, Yeung M, Vu L, Yen SS. Effects of [Nle27]GHRH(1-29)-NH2 on the immune system of aging men and women. JCEM 1997;82:3590–6. PMID 9360512 🔴 (same cohort)
  • Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007;146:104–15. PMID 17227934
  • Barkan AL. Growth hormone as an anti-aging therapy — do the benefits outweigh the risks? Nat Clin Pract Endocrinol Metab 2007;3:508–9. PMID 17534272
  • Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357:2359–70. PMID 18057338 [Tesamorelin context]

Peer-reviewed secondary / review

  • Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999;12(2):139–57. PMID 18031173
  • Verbalis JG, et al. Hormones and Aging: An Endocrine Society Scientific Statement. JCEM 2023

Academic secondary references

  • PubChem CID 16132413 — Sermorelin (free base)
  • PubChem CID 16132412 — Sermorelin acetate
  • DrugBank DB00010 — Sermorelin
  • IUPHAR/BPS Guide to PHARMACOLOGY — GHRH receptor entry

Full citation list and source-class labels available in source file sermorelin_sci_2026-05-15_C16.md.

Community (Pass 2 layer)

Substantive retrieval-limitations disclosure carried into §7B above. Key named community sources cited in this composition:

  • Defy Medical resource page on sermorelin, dosing instructions, and product page (defymedical.com / defymedicalstore.com)
  • Olympia Pharmaceuticals sermorelin dosage chart
  • Eden Sermorelin Dosage Calculator (tryeden.com)
  • HydraMed sermorelin pricing and protocol pages
  • Sermorelin.com dosage and “Sermorelin for Sleep” pages
  • Swolverine sermorelin dosage guide; Swolverine sermorelin for bodybuilding
  • PRAMAH / The Haven Tampa “Sermorelin/Ipamorelin”
  • Strive Pharmacy compounded sermorelin practitioner’s guide
  • Huberman Lab Podcast #189 “Benefits & Risks of Peptide Therapeutics” (April 2024)
  • Huberman Lab “Dr. Craig Koniver: Peptide & Hormone Therapies”
  • FastLifeHacks Andrew Huberman’s Peptide List
  • Peter Attia, The Drive #274 (with Derek / MPMD)
  • Ben Greenfield Life “Growth Hormone-Releasing Peptides Deep Dive”; “How To Use Growth Hormone Stacks”; “Are Peptides Safe? Are They Legal?”; Evan Miller / Gameday podcast appearance
  • Frier Levitt “Regulatory Status of Peptide Compounding in 2025” (April 2025)
  • Lexology / Reed Smith “FDA removes certain peptide bulk drug substances from Category 2” (October 1, 2024)
  • MESO-Rx forum thread “Starting Sermorelin – Rx Dosing Seems Low vs Clinical Studies, Considering Switch to Tesa” (2024) — retrieval-limited
  • MESO-Rx zybiopeptides thread (May 2026)
  • Meso-Morph forum “Sermorelin stacking with SARMs” thread (2024)
  • PeptideDeck sermorelin guides; HealingMaps sermorelin vs CJC-1295 vs Ipamorelin (2026); Livv Natural sermorelin vs CJC-1295 vs Ipamorelin
  • Telehealth Ally Defy Medical review; The Biological Edge Defy Medical Review (2025)
  • The Peptide Catalog 2026 tesamorelin pricing piece
  • Fuel Nutrition “Best Peptide Advice From Huberman Lab, The Drive, FoundMyFitness, & Tim Ferriss (2021–2026)”
  • Vitalize Medical, Hone Health, Oath Research peptide-regulatory write-ups
  • Project Biohacking compounding pharmacy peptides 2025 guide

Full numbered citation list with URLs and access dates in source file sermorelin_com_2026-05-15_C85.md.

14. Audit / Refresh Trail

  • Composed: 2026-05-15
  • Science-layer source: sermorelin_sci_2026-05-15_C16.md (Pass 1; refresh date 2026-05-15; prior coverage in Group_B_GH_GHRH_Secretagogues_2026-05-09.md and Growth_Hormone__GHRH_Analogues__and_GH_Secretagogues__Comprehensive_Scientific_and_Regulatory_Review_2026.md)
  • Community-layer source: sermorelin_com_2026-05-15_C85.md (Pass 2; compiled 2026-05-15)
  • Section 4 Last regulatory review: 2026-05-15
  • Two-molecule calibration block: Not applicable — sermorelin is a single canonical molecule (GHRH(1-29)-NH₂). Confirmed at composition.
  • Next refresh triggers:
    • Any modern multi-center placebo-controlled RCT of sermorelin in adults (the single largest evidence-base shift possible for this entry)
    • Any updated Cochrane systematic review of GHRH analogues or GH secretagogues in healthy adults
    • Any change to WADA Prohibited List Section S2.2.4 (annual cycle, effective each 1 January)
    • Any FDA action affecting §503A compounding access for sermorelin specifically (e.g., a future PCAC nomination, or a re-categorization)
    • Any change to TGA scheduling of sermorelin or related GHRH analogues
    • Any further EMD Serono / successor regulatory filings (e.g., re-application by a new sponsor)
    • Any high-profile WADA sanction with sermorelin as a named substance
    • Material shift in the grey-market vendor landscape (further FDA enforcement, vendor scandals, COA failures)
    • Any new mainstream-podcast or named-figure endorsement or repudiation (Huberman, Attia, Rogan, Greenfield, Campbell, MPMD)
    • Any peer-reviewed Reddit-corpus retrieval that closes the Pass 2 retrieval gap
    • Any new published characterisation of community-reported tachyphylaxis dose-response